Blepharitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Blepharitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Blepharitis - Pipeline Review, H2 2016', provides an overview of the Blepharitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Blepharitis
- The report reviews pipeline therapeutics for Blepharitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Blepharitis therapeutics and enlists all their major and minor projects
- The report assesses Blepharitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Blepharitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Blepharitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Blepharitis Overview 6
Therapeutics Development 7
Pipeline Products for Blepharitis - Overview 7
Blepharitis - Therapeutics under Development by Companies 8
Blepharitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Blepharitis - Products under Development by Companies 12
Blepharitis - Companies Involved in Therapeutics Development 13
Allergan Plc 13
InSite Vision Incorporated 14
Kala Pharmaceuticals, Inc. 15
NicOx S.A. 16
Quorum Innovations LLC 17
Senju Pharmaceutical Co., Ltd. 18
Blepharitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AGN-195263 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
azithromycin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
azithromycin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dexamethasone acetate - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
fluticasone propionate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ISV-405 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
loteprednol etabonate - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Qi-305 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Blepharitis - Dormant Projects 40
Blepharitis - Product Development Milestones 41
Featured News & Press Releases 41
Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults 41
Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Number of Products under Development for Blepharitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Blepharitis - Pipeline by Allergan Plc, H2 2016 13
Blepharitis - Pipeline by InSite Vision Incorporated, H2 2016 14
Blepharitis - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 15
Blepharitis - Pipeline by NicOx S.A., H2 2016 16
Blepharitis - Pipeline by Quorum Innovations LLC, H2 2016 17
Blepharitis - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Blepharitis - Dormant Projects, H2 2016 40